Close Menu


Also at the conference, Agilent and Bruker introduced new mass specs, Thermo Fisher trumpeted its newest MS platforms, and Waters continued pushing its Acquity UPLC.

The firm placed $100M worth of notes due in February 2020.

The marketing and supply agreement covers the Daisogel bulk packing materials and media for process chromatography and HPLC columns.

The proceeds will primarily be used to repay other outstanding debt.

In the midst of reporting a 3 percent revenue increase for Waters fourth quarter, CEO Douglas Berthiaume said a planned new quadrupole instrument launch, shipping of its Synapt G2 instrument, and mass spec-based stimulus grants could portend a strong year for the company's mass spec business.

The system is designed for researchers "who have been attracted by the promise of UPLC but remain reluctant to change largely because of their comfort levels with existing HPLC systems and techniques," a Waters official said.

Waters' revenues for Q4 were down 1 percent organically, with flat instrument sales for its Waters division.

Marc Casper made his remarks at the annual JP Morgan Healthcare Conference this week, where other mass-spec vendors said the economic meltdown wasn't as bad as originally feared.

Officials from the company said Thermo Fisher's R&D investments would target mass spectrometry, specialty diagnostics, and bioscience reagents.

A Beckman Coulter official provided an update on revenue guidance and the firm's pending molecular diagnostics system; while an Agilent executive discussed the company's pending Varian acquisition and new UHPLC system.


The chief executive of the National Health Service in England is to call for tumor-agnostic drugs to be "fast-tracked," according to the Times.

Researchers in Australia are sequencing the Wollemi pine tree to try to protect it from extinction, Australia's ABC News reports.

Computerworld ranks Illumina as one of the top midsize organizations to work at in IT.

In Genome Research this week: links between biological aging and mutations affecting epigenetic regulators; long-read sequencing-based strategy to map chromatin accessibility; and more.